Article
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19…
medRxiv: the preprint server for health sciences · 2021 · Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta SJ, Pollok RC, Raine T, Smith PJ, Verma AM, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T, Contributors to the CLARITY IBD study.
Key facts
| Title | Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines |
|---|---|
| First author | Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta SJ, Pollok RC, Raine T, Smith PJ, Verma AM, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T, Contributors to the CLARITY IBD study. |
| Journal | medRxiv : the preprint server for health sciences |
| Published | Mar 31, 2021 |
| DOI | 10.1101/2021.03.25.21254335 |
| Devices mentioned | K780428, K791373, K801244, K820613, K820614, K820942 |
| Product codes mentioned | CFE, JHI, JLW |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1